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Abstract
Motivation: Multiple Reaction Monitoring (MRM)-based targeted proteomics is increasingly being
used to study the molecular basis of disease. When combined with an internal standard, MRM
allows absolute quantification of proteins in virtually any type of sample but the development and
validation of an MRM assay for a specific protein is laborious. Therefore, several public repositories
now host targeted proteomics MRM assays, including NCI’s Clinical Proteomic Tumor Analysis
Consortium assay portals, PeptideAtlas SRM Experiment Library, SRMAtlas, PanoramaWeb and
PeptideTracker, with all of which contain different levels of information.
Results: Here we present MRMAssayDB, a web-based application that integrates these repositories
into a single resource. MRMAssayDB maps and links the targeted assays, annotates the proteins
with information from UniProtKB, KEGG pathways and Gene Ontologies, and provides several
visualization options on the peptide and protein level. Currently MRMAssayDB contains>168K
assays covering more than 34K proteins from 63 organisms;>13.5K of these proteins are present
in>2.3K KEGG biological pathways corresponding to>300 master pathways, and mapping
to>13K GO biological processes. MRMAssayDB allows comprehensive searches for a targeted-
proteomics assay depending on the user’s interests, by using target-protein name or accession
number, or using annotations such as subcellular localization, biological pathway, or disease or
drug associations. The user can see how many data repositories include a specific peptide assay,
and the commonly used transitions for each peptide in all empirical data from the repositories.
Availability and implementation: http://mrmassaydb.proteincentre.com
Contact: christoph@proteincentre.com or yassene@proteincentre.com
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Targeted proteomics has become the method of choice for protein
quantification which can be used to reproducibly quantitate large
sets of proteins in a high-throughput manner, up to hundred
proteins in 45 min (Keshishian et al., 2009; Percy et al., 2014;
Picotti et al., 2013). Targeted proteomics methods are typically per-
formed using triple quadrupole in the Multiple Reaction Monitoring
(MRM) mode, or using Orbitrap mass spectrometers in the Parallel
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Reaction Monitoring (PRM) mode. In an MRM experiment, the
first quadrupole is used to isolate a particular precursor peptide ion,
the second quadrupole is used for collision-induced dissociation,
and the third one is used to isolate a characteristic fragment ion. In
PRM, only the last step differs in that all ions are monitored.
In scheduled LC/MRM-MS analysis, specific precursor/product ion
pairs are monitored while the peptide is eluting from the liquid chro-
matography system, which allows quantitation of a large number of
peptides and, by inference, the corresponding proteins (Mohammed
et al., 2014).
Designing and validating a new MRM/PRM assay is a laborious
process. It is a multistep workflow that, in addition to performing
wet-laboratory experiments, requires integration of prior knowledge
with experimental data. This information includes for example the
uniqueness of the proxy peptide (surrogate for a protein of interest)
within a particular proteome, its retention time under specific LC
conditions, the corresponding precursor/fragment ion pairs and
more. The very first step in the assay design workflow is a good ex-
ample of the challenges that one can face. Selecting the most suitable
MRM peptide from a target protein includes enforcing almost 30
rules (Mohammed et al., 2014), where an important aspect is
whether a peptide has been previously observed in MS/MS analyses
and thus is known to be detectable—and this type of data can be
found in several online public repositories (Liebler and Zimmerman,
2013).
There is no doubt that sharing already designed and validated
targeted proteomics assays can save a lot of work for scientists and
researchers planning to perform MRM or PRM experiments. Well-
established resources for MRM-based targeted proteomics data in-
clude: PeptideAtlas SRM Experiment Library (PASSEL) (Farrah
et al., 2012), NCI’s Clinical Proteomic Tumor Analysis Consortium
(CPTAC) (Whiteaker et al., 2014), PanoramaWeb (Sharma et al.,
2014), SRMAtlas (Kusebauch et al., 2016) and PeptideTracker
(Mohammed et al., 2016). New entries are added constantly to these
repositories by different groups, whereas some repositories are spe-
cific like CPTAC which hosts mainly tumor assays, others are more
generic for any targeted proteomics experiment like PASSEL. Some
repositories store the raw data like PanoramaWeb, while others
put emphasis on including the full sample preparation protocols
like CPTAC and PeptideTracker. Also, for some protein entries,
PeptideTracker lists the determined protein concentration ranges in
samples, as measured by MRM.
PASSEL is a generic data repository from the Institute of System
Biology. New MRM experimental results and the corresponding
raw data can be submitted by the user (Farrah et al., 2012), (www.
peptideatlas.org/passel/), which—along with the corresponding
internally-processed results—are made available to the research
community.
The assay portal of CPTAC (Whiteaker et al., 2014) from the
National Cancer Institute (NCI), (http://assays.cancer.gov), serves as
an open-source repository of well-characterized targeted proteomic
assays. Its main goals are to enable robust quantification of all
human proteins and to standardize the quantification of targeted
MS-based assays (Whiteaker et al., 2016). Submission to the portal
is done by the consortium partners.
PanoramaWeb (Sharma et al., 2014) is an online resource
for storing, sharing and analyzing targeted proteomic experiment
processed by Skyline software (MacLean et al., 2010). The
PanoramaWeb repository (https://panoramaweb.org) provides a
detailed view for the peptide, including chromatograms for the
precursors in of all the replicates and also plots the peak area
integrations.
PeptideTracker (Mohammed et al., 2016) (http://peptidetracker.
proteincentre.com) was introduced as a knowledge base that is
designed for collecting and storing information on protein concen-
tration ranges in biological tissues along with the detailed descrip-
tion of the assays that were used. The information in PeptideTracker
has been compiled from different experiments, along with the acqui-
sition protocols and conditions used. While submission of new data
is possible, the listed assay entries are mainly for human and mouse
tissues due to the work history of the group behind PeptideTracker.
Because these data repositories and knowledge bases on targeted
proteomics assays were introduced with different goals in mind, it is
understandable that the information hosted is heterogeneous. In this
context, MRMAssayDB provides the first tool to obtain comprehen-
sive information on all available targeted proteomics assays in all of
these community-wide online resources.
2 Materials and methods
2.1 MRMAssayDB data collection
Currently, MRMAssayDB is populated with MRM-based targeted
proteomics assay data from PASSEL (Farrah et al., 2012), CPTAC
(Whiteaker et al., 2014), PanoramaWeb (Sharma et al.,
2014), SRMAtlas (Kusebauch et al., 2016) and PeptideTracker
(Mohammed et al., 2016). Ultimately, the goal is to combine data
that resides in different targeted proteomics repositories, and pro-
vide users with a unified view of available targeted proteomics
assays.
MRMAssayDB keeps various information on the protein assays
including UniProtKB accession number (UniProt_Consortium
2011), protein name, gene name, organisms, peptide sequence,
uniqueness in the proteome, peptide presence of isoforms, labeled
internal standard used and, importantly, a hyperlink of each entry
to the relevant targeted proteomics resources from which the
information was obtained (Supplementary Fig. S1). The datatables
in MRMAssayDB are updated periodically. For this, new data
from all five repositories is retrieved, matched with UniProtKB
(UniProt_Consortium 2011) and other databases, and compiled
automatically on a monthly basis. The uniqueness of the peptide to
the target protein is re-assessed in each compilation as it may change
with the discovery of new proteins. Here, a ‘unique peptide’ means
that its sequence is present only in the specific protein and/or its iso-
forms, and both these levels are annotated. This means that users
have available to them information on whether a peptide assay can
be used to quantify a specific isoform, or whether it can be used to
test if a gene model with any splice isoform is expressed at the pro-
tein level.
2.2 Search functionality
Because of the richness of the collected data, having a good search
algorithm is essential. MRMAssayDB allows searching the assays
and filtering as well as downloading the search results in various
ways, based on the user’s interest. The assays can be searched based
on partial protein name, protein accession, partial peptide sequence,
biological pathway involvement, or involvement in disease (Fig. 1).
After the search results are present on the screen, additional filters
can be applied to each column, columns can be blended and viewed,
and a final report of the search results can be downloaded.
MRMAssayDB also provides an advanced search option where mul-
tiple search terms specific to different data types can be combined,
e.g. protein name and subcellular location, or gene name, organism
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advanced search function whenever possible because combined
queries limit the volume of data that has to be loaded, and thereby
improve responsiveness.
2.3 Domain, post-translational modifications and
disease-causing mutations
Mutations and post-translational modifications (PTMs) are import-
ant in the study of health and disease, and more data is continuously
becoming available on the positions of disease-related mutations
and PTMs on the protein (Lam et al., 2016; Nehrt et al., 2012).
While the majority of MRM/PRM targeted proteomics assays
are based on non-modified peptides, it is important to have updated
information on whether the proxy peptide selected carries a muta-
tion or PTM, or not. We have combined data on known disease-
causing mutations and PTMs, and mapped it to the assays in
MRMAssayDB. To visualize the variations, PTMs and important
UniProtKB features, we have added a recently-released visualization
tool, ProtVista (Watkins et al., 2017), that shows the proxy peptide,
protein sequence features in the UniProtKB, experimental proteo-
mics and variation public datasets (Fig. 2). The functional, position-
al and variant information was obtained from the EBI Protein API
(Nightingale et al., 2017).
2.4 Structural data
In targeted proteomics methods that are based on surrogate or proxy
peptides, it is sometime of interest to know the exact position of the
peptide in the 3D structure of the protein. Therefore, 3D protein
struc-tures in the unbound (free) and bound (complex) states that in-
clude the particular peptide have been extracted from Protein
Databank (PDB) (Berman et al., 2002). PDB structures were selected
using two criteria: (i) the constructs used for the structure determin-
ation experiment contained the peptide sequence of interest, and
(ii) there is visible electron density for the peptide. IUPred
(Dosztányi et al., 2005) software was used to predict the structural
disorder, and IUPred outputs scores (ranging between 0 and 1)
are included for each residue; with scores that are>0.5 indicating
disordered residues (the ‘short’ mode of IUPred was used)
(Supplementary Fig. S2A–E).
2.5 Biological pathways
MRMAssayDB maps all available assays to the entries in the KEGG
pathway database (Kanehisa and Goto, 2000), and extracts and dis-
plays the entire network of which the assay is a part. The genes or
proteins in the pathway maps are color coded, with violet indicating
the assay that the user searched for in MRMAssayDB, and maroon
and orange indicating that there is an assay available for a protein
or gene, while rectangular green boxes represent genes or proteins in
the pathway without assays in MRMAssayDB. All color-coded
boxes are linked to the data in MRMAssayDB via hyperlinks. With
one single interactive plot, the user can see the coverage of the bio-
logical pathway using available assays (Fig. 3A).
2.6 Protein–protein interactions
For each assay, MRMAssayDB extracts the known protein–protein
interactions from the STRING database (Szklarczyk et al., 2015).
The same color-coding scheme for pathway analysis was used when
mapping the genes or proteins onto the protein–protein-interaction
network, while white boxes represent non-mapped genes in the
interactome (Fig. 3B).
2.7 Functional data
MRMAssayDB links the targeted proteomics protein assays to the
functional data annotations for the protein as represented in the
Fig. 1. MRMAssayDB homepage with simple and advanced search functional-
ities, along with some statistics on its content
Fig. 2. A visual representation of a protein and its MRM peptide assays along
with other annotations displayed in MRMAssayDB. The example in the figure
is from cellular tumor antigen p53 protein (P04637) showing UniProtKB fea-
tures, experimental proteomics and variants obtained from public datasets
using the EBI ProtVista tool after extending it with MRMAssayDB data
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Gene Ontology (GO) annotations from the QuickGO (Binns et al.,
2009) web-based portal (Supplementary Fig. S3). This functional
data includes information on the three most general GO terms:
Biological Process, Molecular Function and Cellular Component.
Briefly, Molecular Function explains what a gene product does at
the biochemical level. Biological Process explains a broad biological
objective. Cellular Component defines the location of a gene prod-
uct, within cellular structures and within macromolecular com-
plexes (Gene_Ontology_Consortium 2011).
2.8 Implementation
All the routines in MRMAssayDB are written in the Python 2.7 pro-
gramming language (www.python.org). The user web interface was
developed using the Django 1.8 framework (https://djangoproject.
com), and displays plots are generated on the fly using JavaScript.
JSmol is used to visualize the 3D protein structures interactively
(http://wiki.jmol.org/index.php/JSmol#JSmol). We preferred JSmol
over Jmol because JSmol is a JavaScript applet and does not require
any Java (popup window) authorization. Jvenn (Bardou et al., 2014)
and Cytoscape.js (Franz et al., 2016) were used to plot the inter-
active Euclidean diagrams (Fig. 1) and PPI networks (Fig. 3B), re-
spectively. The metadata from PASSEL (Farrah et al., 2012),
CPTAC (Whiteaker et al., 2014), PanoramaWeb (Sharma et al.,
2014), SRMAtlas (Kusebauch et al.), PeptideTracker (Mohammed
et al., 2016), UniProt (UniProt_Consortium 2011), PDB (Berman
et al., 2002), KEGG (Kanehisa and Goto, 2000), STRING
(Szklarczyk et al., 2015) and QuickGO (Binns et al., 2009) are auto-
matically retrieved using routines written in Java (www.oracle.com/
java/index.html), Python and Selenium Webdriver (http://www.sele
niumhq.org).
3 Results
MRMAssayDB captures various types of data and information from
MRM/PRM experiment repositories as well as proteomic and path-
way information from targeted proteomics assays, and makes
all linked information accessible through a single web interface.
Our system provides up-to-date information on thousands of tar-
geted proteomics assays. Currently, entries for 168 404 peptide
assays are included, covering more than 34 740 proteins from 63
species (Table 1). These proteins correspond to 13 102 biological
processes, 4886 molecular functions, and 1929 cellular components.
Supplementary Figure S4 shows this trend exemplified in the top
GO terms for human proteins. As of March 2018, PanoramaWeb
(Sharma et al., 2014), CPTAC (Whiteaker et al., 2014), SRMAtlas
(Kusebauch et al.) and PASSEL (Farrah et al., 2012), and
PeptideTracker (Mohammed et al., 2016) contain information on
thousands of assays with transitions for the labeled and label-free
forms of the peptide (Table 2). While each of the five resources was
developed for a specific goal, the information hosted by them is
complementary (Fig. 1), and together they form a valuable founda-
tion for MRM based targeted proteomics.
The information on these 168K proteotypic peptide assays is
based on the 177 327 MRM assays currently available in the tar-
geted proteomics community repositories. The difference in the
numbers is due to assays that are not unique to the proteome of a
specific organism (using UniProtKB as the reference). A user can
nevertheless use the advanced search function to upload his own
protein sequences in FASTA format, and all 177K assays will be
searched and suitable proteotypic peptide assays will be reported in
the results.
Fig. 3. Pathway and PPI Viewer in MRMAssayDB. (A) An example of Complement and Coagulation cascades for tissue factor protein (gene name F3) from the
KEGG database. (B) Protein–protein interaction network of the F3 gene. All nodes in (A) and (B) can be searched for targeted assays in MRMAssayDB via the web
interface, using a single click
Table 1. The five organisms with the highest number of entries in
MRMAssayDB (March 2018)
Organism name Number of unique peptide assay entries
Homo sapiens (human) 101 613 (covering 19 777 proteins)
Saccharomyces cerevisiae (yeast) 47 946 (covering 6478 proteins)
Escherichia coli 3420 (covering 2363 proteins)
Mus musculus (mouse) 5327 (covering 2304 proteins)
Mycobacterium tuberculosis 5892 (covering 1681 proteins)
Others 4211 (covering 2137 proteins)
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Because MRMAssayDB uses an integrative approach and maps
data from multiple repositories, it allows a new view of every assay
and shows how many data repository a particular assay is in. For ex-
ample one protein may have multiple proteotypic peptide assays al-
ready developed, validated, and in used. The proteotypic peptide
which has been successfully used by the largest number of users
would probably be a good choice if one is interested in simple quan-
tification of the protein. In addition, MRMAssayDB lists the most
common transitions for each peptide MRM assay. Keeping in mind
that all transitions originate from actual validated assays used in one
or more laboratory, the most commonly used transitions are those
ions which appearing most frequently in the assays for a specific sur-
rogate peptide. Although there may be various ways of determining
the ‘best’ transitions—e.g. those with the highest intensity, best peak
shape, or fewer interferences, we assume that if various scientists
have followed various methods to determine the transitions and val-
idate them in actual experiments, then the best transitions will be
those that appear most frequently in various experiments. Keeping
in mind that the user can sort and filter any column in the
MRMAssayDB results datatable, the user can, for example, identify
the most commonly used assay for a specific protein and its best
transitions with only few clicks.
Not all of the assays in the online repositories are based on
unique peptides in the proteome. Therefore, for all peptides that are
included in the MRMAssayDB, a uniqueness test is performed and
the results are reported next to each peptide. Currently 93% of all
assays are based on unique peptides (Table 3). Using the EBI stand-
ard tool for the graphical representation of protein sequence fea-
tures—ProtVista tool (Watkins et al., 2017), the proxy peptide of
the target protein can be compared to the various protein-sequence
features in UniProtKB, and experimental proteomics and sequence
variation data. As example of the human protein P53_HUMAN
which functions as a tumor suppressor (25) is shown in Figure 2,
and one can see that the proxy peptide (residues 182–196) contain a
modified residue and two disease-causing mutations.
The protein structure viewer facilitates the exploration and visu-
alization of 3D protein structures and allows the user to visualize
the region of origin of the proxy peptide. This allows the user to
visually explore whether the surrogate peptide originated from the
surface or was embedded deeper in the folded protein, or whether
the peptide formed part of an alpha helix or a beta sheet. In case of
multiple peptide assays for one protein, the user can choose an assay
based on the specific region of the proxy peptide in the 3D structure
of the protein. An example showing ubiquitin-like ISG15 protein
and its assay using the surrogate peptide LAVHPSGVALQDR is
presented in Supplementary Figure S2.
From all entries in MRMAssayDB, we were able to map a total
of 13 568 proteins to 384 KEGG master biological pathways.
Figure 4 shows a few examples of these pathways, such as the P13K-
AKT signalling pathway in humans which includes 524 proteins of
which 342 are present with assays in MRMAssayDB, the KEGG
pathways in cancer for which there are 522 assays available for
human (Fig. 4). Figure 4 provides an insight into how the integrative
approach of combining the five major targeted-proteomics assay
repositories can provide improved coverage compared to an individ-
ual repository. Approximately only two-third of all human proteins
are currently associated with metabolic pathways (based on entries
retrieved from KEGG and UniProtKB in March 2018). Using the in-
formation in MRMAassayDB on the protein in volvement in bio-
logical pathways, assays can be chosen and used to further
characterize existing pathways, or—as not all proteins are present in
KEGG—an assay can be chosen to find new undocumented involve-
ment of a protein in a pathway. For pathway visualization, all nodes
(genes/proteins/enzymes) can be interactively used, as they are
hyperlinked to each corresponding entry and are color-coded and
highlighted on the pathway graphs (Fig. 3A).
As the amount of available protein–protein interaction data
increases, it is common for researchers to analyze their proteins of
interest as a part of a system of dynamic interactions. The protein–
protein interaction network of each assay in MRMAssayDB is dis-
played using the Cytoscape Web application (Franz et al., 2016).
The network can be obtained from the search-results table
(Supplementary Fig. S1). The color-coded network (See Section 2)
(Fig. 3B) provides helpful insights into the available targeted proteo-
mics assay for which interaction.
MRMAssayDB also maps all entries to their Gene Ontology an-
notation. The current assays map to 13102 biological processes,
4886 molecular functions, and 1929 cellular components. Most of
the available assays for human samples are associated with
G-protein coupled receptor signaling pathway (99%) and signal
Table 2. Assays in the targeted proteomics repositories
Database name Number of unique peptide assay entries
CPTAC 1405 assay covering 808 proteins
PanoramaWeb 41 998 assay covering 8625 proteins
PASSEL 20 496 assay covering 7553 proteins
PeptideTracker 5640 assay covering 3281 proteins
SRMAtlas 118 098 assay covering 25914 proteins
Table 3. Assay specificity to protein isoform based on repository
data
Database name Peptide uniqueness
in proteome (%)








Fig. 4. Top 10 KEGG pathways with targeted proteomics assays in humans.
Above each bar is the number of proteins with assays in MRMAssayDB, the
total number of proteins corresponding to that pathway, and—in parenthe-
ses—the corresponding percent coverage
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transduction (99.5%). On one hand, this indicates the possibility of
using the assays collected in MRMAssayDB to characterize diverse
biological process (Supplementary Fig. S4), and, on the other hand,
it shows the preferences in the targeted proteomics community
toward developing assays to characterize biological processes.
The majority of the molecular functions and cellular components
were associated with protein binding and cytosol (Supplementary
Fig. S4).
4 Conclusions
MRMAssayDB is a freely available web-based resource for accumu-
lating available targeted proteomics assays in the community.
It retrieves information from five major MRM and PRM targeted-
proteomics assay portals, and the data repositories: PASSEL,
PanoramaWeb, CPTAC assay portal, SRMAtlas and PeptideTracker.
The collected information is integrated and annotated with additional
information on the involvement of biological pathways, protein–pro-
tein interaction, Gene Ontology terms, known PTMs and disease-
associated mutations, disease involvement, etc. MRMAssayDB will
help scientists and researchers attempting to perform a targeted pro-
teomics experiment to easily find the suitable assay and will accelerate
sharing the assays between scientists.
MRMAssayDB shows how many data repositories reported
each assay, allowing results to be sorted and enabling the user to im-
mediately see which assay was used successfully by most users.
Furthermore, for each MRM peptide assay, the common transitions
appearing most frequently in all available assays from different
repositories and instruments are listed. Users can also upload own
protein sequences to search for suitable existing assays.
The application combines the strengths of Java, Python, Ajax,
JavaScript, Selenium Webdriver and Django with a suite of inte-
grated bioinformatics tools. Ultimately, MRMAssayDB supports
basic and advanced search queries, as well as the possibility of filter-
ing and sorting the search results. The software has also an advanced
Application Program Interface allowing a query to be sent in an
automated manner. As new datasets become available, we intend to
continue to integrate them into the database. The data entries are
updated automatically at the beginning of each month.
MRMAssayDB is unique in both its integrative approach and the
comprehensiveness of information provided on the available
targeted-proteomics assays in the community–wide online resources.
The type of empirical, detailed information included in this tool for
each peptide is required and essential for the planning of MRM
experiments. Access to the software is available free of charge, at
http://MRMAssayDB.proteincentre.com/.
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